Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Open-Label Extension Study of Oral Levosimendan
Sponsor: Tenax Therapeutics, Inc.
Summary
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.
Official title: A Multicenter, Open-Label, Long-Term Extension Study for Oral Levosimendan (TNX-103)
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
800
Start Date
2026-03-13
Completion Date
2029-03
Last Updated
2026-03-19
Healthy Volunteers
No
Interventions
TNX-103
Open-label oral levosimendan 1-3mg
Locations (5)
Tenax Investigational Site
Chicago, Illinois, United States
Tenax Investigational Site
Minneapolis, Minnesota, United States
Tenax Investigational Site
Rochester, Minnesota, United States
Tenax Investigational Site
St Louis, Missouri, United States
Tenax Investigational Site
Charleston, South Carolina, United States